Bayerische Motoren Werke ADR (BMWYY)

NEWARK, CA – In a decisive move to salvage its position in the increasingly crowded electric vehicle landscape, Lucid Group, Inc. (NASDAQ: LCID) announced today, April 14, 2026, the appointment of Silvio Napoli as its new Chief Executive Officer. The hiring of Napoli, an outsider hailing from the industrial sector, marks

In a decisive move to secure its long-term viability and pivot toward mass-market appeal, Lucid Group (NASDAQ: LCID) announced today, April 14, 2026, a comprehensive $1.05 billion strategic financing package. The capital infusion, which includes a registered public offering and significant investments from existing partners, is designed to provide

Today, April 14, 2026, Lucid Group, Inc. (NASDAQ: LCID) finds itself at a defining moment in its decade-plus journey. Once hailed as the "Tesla-killer" during the luxury EV euphoria of the early 2020s, the California-based automaker has evolved into a case study of high-stakes engineering versus the brutal realities of automotive manufacturing. With the announcement [...]

BMW’s hydrogen vehicle program has moved from extended research into active production planning, and the iX5 Hydrogen is the clearest expression of that shift. Industry reaction has been genuinely positive, though tempered by a recognition that hydrogen’s commercial future depends heavily on factors beyond any single vehicle’s specifications.

Glioblastoma is a deadly type of brain cancer which progresses rapidly and kills victims within months. For nearly two decades, no significant progress has been made in developing an effective treatment against this malignancy. Now, a new preclinical study using animal models has unveiled a potential breakthrough that could eliminate these tumors.

As of April 13, 2026, the semiconductor landscape has transitioned from a period of "scarcity at any cost" to a sophisticated battle for efficiency and vertical integration. At the heart of this transition stands ON Semiconductor Corporation (NASDAQ: ON), now widely known as onsemi. Once regarded as a reliable but uninspiring supplier of commodity components, [...]

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that the first patient has been dosed in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia, shortly after site activation on March 31, 2026. The milestone follows regulatory approval and highlights progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms, as the company expands trial sites and targets a large unmet need in a condition with no FDA-approved pharmacological treatments.

DeKalb, IL - April 10, 2026 - Motor Works, DeKalb's trusted auto repair facility since 1984, continues to redefine what it means to be a dealership alternative in a college town where several major automotive brands have no local representation. Under the leadership of owner Meghan Huber, who purchased the business from her father five years ago, Motor Works has experienced explosive growth while maintaining the family-friendly, education-first approach that has made it a community staple trusted by DeKalb families.

First-quarter sales for U.S. automakers were rough, but Ford had one significant decline that could be costly.

After seven years of annual sales declines, Stellantis investors are desperate for sales to gain traction and drive results higher. Here's the good news.

The immune system is capable of identifying and attacking cancer cells in the body. This process depends on the tumor producing damaged RNA, which then sticks to cell surfaces and provides the antigens that the body identifies as foreign and therefore targets. However, a natural mechanism within the body that removes faulty RNA ironically aids many cancers to avoid detection and therefore limit immune system responses to the disease.

LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical innovation and next-generation radiotherapy ( ibn.fm/C7Kms ).

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights, including Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence and CardioInnovate360(TM) to support cardiovascular therapy development.

Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large and complex biomedical datasets, which are often incredibly difficult and time-consuming to go through manually.

Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat.

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

According to a poll conducted by Gallup in March, Americans are most concerned about healthcare . This finding is notable given the escalation in the Iran war and the way events in the Middle East are currently dominating news headlines.

Electric vehicles (EVs) are taking over roads worldwide, but charging them can be tricky when traveling between regions with different standards. That’s where the CCS2-GBT V2 400A adapter comes in. Designed by a leading EV charger solution factory, this powerful adapter lets you charge GB/T-compatible cars like the Zeekr 001, BMW i3, and Avarta at ultra-fast CCS2 stations—no more worrying about incompatible plugs or slow charging speeds.

A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the rapidly growing market for cancer immunotherapy. The report puts the valuation of this market in 2025 at $144.8 billion and projects that it will expand to $311.4 billion by 2031.

For off-road enthusiasts dreaming of the ultimate European adventure, Enduro Park Isábena stands out as a top destination. Nestled in the heart of the Spanish Pyrenees, this certified BMW Motorrad off-road center offers everything needed to experience enduro at its best — breathtaking landscapes, professional guides, and the freedom to explore Europe on two wheels.

Excellent brake pads, not only excellent braking performance, but also has the characteristics of braking comfort, brake pads do not hurt discs, wheels do not fall dust. The advantages and disadvantages of brake pads determines the size of the vibration generated by the brake pads during braking, serious noise pollution, affecting the comfort of members and even physical and mental health, but also cause fatigue damage to automotive parts, buried brake failure and other dangers.

The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for rare diseases.

QIAPO, involving BMW and Infineon, validates hybrid quantum-classical computing. UK startup Quantum Links AI offers a commercial platform routing workloads between classical and quantum systems, integrating with AWS and IBM to deliver real-world enterprise benefits.